San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has opened an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) over allegations that the company misled investors about the safety of its lead drug candidate ARD-101, ahead of an October 13, 2026 deadline for shareholders to seek lead plaintiff status in a pending securities class action.